Soya-based infant formulas (SIF) containing soya flour were introduced almost 100 years ago. Modern soya formulas are used in allergy/intolerance to cows' milk-based formulas (CMF), post-infectious diarrhoea, lactose intolerance and galactosaemia, as a vegan human milk (HM) substitute, etc. The safety of SIF is still debated. In the present study, we reviewed the safety of SIF in relation to anthropometric growth, bone health (bone mineral content), immunity, cognition, and reproductive and endocrine functions. The present review includes cross-sectional, case -control, cohort studies or clinical trials that were carried out in children fed SIF compared with those fed other types of infant formulas and that measured safety. The databases that were searched included PubMed (1909 to July 2013), Embase (1988 to May 2013, LILACS (1990 to May 2011, ARTEMISA (13th edition, December 2012), Cochrane controlled trials register, Bandolier and DARE using the Cochrane methodology. Wherever possible, a meta-analysis was carried out. We found that the anthropometric patterns of children fed SIF were similar to those of children fed CMF or HM. Despite the high levels of phytates and aluminium in SIF, Hb, serum protein, Zn and Ca concentrations and bone mineral content were found to be similar to those of children fed CMF or HM. We also found the levels of genistein and daidzein to be higher in children fed SIF; however, we did not find strong evidence of a negative effect on reproductive and endocrine functions. Immune measurements and neurocognitive parameters were similar in all the feeding groups. In conclusion, modern SIF are evidence-based safety options to feed children requiring them. The patterns of growth, bone health and metabolic, reproductive, endocrine, immune and neurological functions are similar to those observed in children fed CMF or HM.
Soya is a product of the Asian plant Glycine max, and it has been part of human nutrition in different parts of the world for more than 2000 years. Soya-based infant formulas (SIF) are products derived from soya, which also have a long history of use around the world (1) . They were used for the first time in the USA in 1909 as food alternatives for infants who had allergy or intolerance to cows' milk-based formulas (CMF). Since that report and until 1960s, these infant formulas have been products entirely derived from soya flour, with different protein availability, digestibility, fibres, phytates and protease inhibitors (2) . The limitations of formulas based on soya flour spurred the development of SIF, in which proteins isolated from soya replaced soya flour during the 1960s. Soya protein isolate (SPI) was extracted from the flake using a slightly alkaline solution and was precipitated at the isoelectric point. The resulting isolate had a purity (15) Only four children assigned sequentially to receive a soyabean infant formula Shepard, 1960 (16) Three cases of hypothyroidism potentially associated with soya intake reported Cowan, 1969 (17) Thirty children, 2-15 months, enrolled in a before -after study; all received a soya infant formula Ament, 1972 (18) Case report of a child with flat intestinal lesions after the use of soya Halpin, 1977 (19) Analysis of soya diets in children with persistent diarrhoea Powell, 1978 (20) Badger, 2002 (61) Narrative discussion on experimental and adult studies; some non-systematic comments on the effects of growth and bone in children fed a soya infant formula Zoppi, 1999 (62) Narrative review of safety; no evidence-based analysis Setchell, 2000 (63) Editorial about the potential effects of isoflavones; not including evidence in children Goldman, 2001 (64) Letter to editor Barret, 2002 (65) Narrative review of basic and some clinical studies related to soya; non-systematic evidence analysis Mendez, 2002 (66) Narrative review of safety of soya formula use (67) Effect of palmolein added to soya or hydrolysate on Ca and PO 4 intestinal absorption Main analysis focus on palm oil; no safety parameters on soya reported Klemola, 2002 (68) Focus on the frequency of allergy to soya; no other safety parameters reported Miniello, 2003 (69) Narrative discussion on experimental and adult studies; some comments on effects on growth and bone; some non-systematic comments on effects on growth and bone in children fed a soya infant formula Tuohy, 2003 (11) Narrative review of clinical and basic papers on soya toxicity Ahn, 2003 (70) Prevalence of soya protein hypersensitivity; no other safety parameters reported Stettler, 2005 (71) Retrospective cohort study on adults to analyse the risk of obesity using different infant formulas Chen, 2004 (9) Narrative review of soya infant formulas; includes studies considered in this review Hoey, 2004 (72) Correlation between the use of soya and microbiota Giampetro, 2004 (73) Forty-eight children fed with soya; no one with precocious puberty; no control group Merritt, 2004 (74) Narrative review of soya infant formulas; includes studies considered in this review Hays, 2005 (75) Use of extensively hydrolysed formulas in allergy Berger-Achituv, 2005 (76) $ 90 %, a high protein digestibility and a balanced high concentration of essential amino acids (3) . During the 1970s, SIF were updated and fortified with L-methionine, L-carnitine and taurine. L-Methionine improved the biological quality of the protein (one of the major criticisms on soya formulas). Other criticisms on SIF are the high levels of aluminium (500-2500 m/l v. 15 -400 and 4-65 mg/l in CMF and human milk (HM)) and the presence of phytates (SIF contain approximately 1·5 % of phytates), which may impair the absorption of minerals and trace elements (4) . (78) Narrative review of soya infant formulas; includes studies considered in this review Pedrosa, 2006 (79) Analysis of palatability of soya and other infant formulas D'Auria, 2006 (80) Letter to editor related to paper by Seppo on the impact of soya formulas on growth Osbron, 2006 (81) Systematic review of the efficacy of soya in preventing allergy Ostrom, 2006 (82) RCT on soya infant formula efficacy for regurgitation treatment Ballmer-Weber, 2007 (83) Clinical characteristics of allergy to soya Fortres, 2007 (84) Portuguese paper on phyto-oestrogen intake and thelarche Halm, 2007 (85) Comparison of phyto-oestrogen levels in urine between children and adults eating soya nuts Turck, 2007 (86) Narrative review of indications of soya and safety issues Song, 2007 (87) Narrative review of the positive and negative effects of soya; studies on soya formula already considered Agostoni, 2007 (88) Effects of soya on weight/age and length/age in children aged 6-12 months; does not include reports on the basal and final measurements of weight-only and height-only differences Wolff, 2008 (89) Cohort study related to puberty in girls analysing exposure to soya, but not to a soya infant formula Zuidmeer, 2008 (90) Prevalence of plant allergies, including allergy to soya, across countries; no safety parameters on infant formulas reported Johnson, 2008 (91) Narrative review of some articles that describe safety issues regarding soya infant formulas, already considered in this review Ngamphaiboon, 2008 (92) Description of CMPA in Thai children Mehr, 2008 (93) Food choices for CMPA; no safety parameters on soya analysed Boucher, 2008 (94) Epidemiological study of the early intake of soya and protective effect against breast cancer Kemp, 2008 (95) Consensus about the best treatment for CMPA; no safety parameters on soya analysed Bernbaum, 2008 (96) Pilot study to evaluate the validity of different techniques to measure breast bud, testicular volume and breast adipose tissue in children; no correlationship study between soya intake and maturation abnormalities Koplin, 2008 (97) Use of soya and allergy to peanuts; no other safety parameters analysed Caminiti, 2009 (98) Analysis of cross-reaction to soya; no other safety parameters analysed Antunes, 2009 (99) Analysis of allergy to soya and extensively hydrolysed formulas; no other safety parameters reported Badger, 2009 (100) Narrative review of some basic and clinical studies of the effects of soya on health; includes some papers considered in this review Lee, 2009 (101) Epidemiological study of the intake of soya during adolescence and protective effect against breast cancer Korde, 2009 (102) Epidemiological study of the early intake of soya and protective effect against breast cancer Guest, 2009 (103) Health economics model of treatment for CMPA; safety parameters on soya not evaluated Palmer, 2009 (104) Urogenital effects of in utero exposure to diethylstilbestrol in males; does not include studies on infant formulas Cederroth, 2009 (105) Effects of soya on male reproductive function; animal studies; does not include paediatric studies on soya infant formulas Vandenplas, 2011 (106) Narrative review on the safety of soya infant formulas; some papers cited are analysed in this review Dias, 2010 (107) Persistence of CMPA and use of different infant formulas; no safety parameters on soya reported Bolca, 2010 (108) Soya isoflavones in breast tissue of women under breast resection Cheng, 2010 (109) Cohort study of soya ingestion during adolescence; not related to infant formulas Terracciano, 2010 (110) Analysis of soya allergy; no other safety parameters reported Tillet, 2010 (111) Informative letter of toxicology classification Nacmias, 2010 (112) Paper related to allergy to soya in neonates; no other safety parameters reported Sladkevicius, 2010 (113) Health economics analysis of soya use Katz, 2010 (114) Paper related to allergy to soya; no other safety parameters reported Patisaul, 2010 (115) Narrative description of biochemical, basic, clinical and epidemiological studies of soya; includes analysis of papers related to soya infant formulas, already considered in this review Donovan, 2010 (116) Description of soya effects on intestinal cell proliferation and antirotavirus effect; no safety parameters on soya reported Dinsdale, 2010 (117) Narrative review focused on animal and human studies on potential soya toxicity; non-systematic analysis concludes that there is no evidence of soya infant formula toxicity in children Wada, 2011 (118) Cross-sectional study of the correlationship between soya in diet and urinary level of sex hormones in boys/girls aged 4 -6 years; no history about soya infant formulas is recorded McCarver, 2011 (119) Exhaustive narrative review focused on animal and human studies; non-systematic analysis concludes that there is no evidence of soya infant formula toxicity in children Kim, 2011 (120) Case -control study in 7-10·2-year-old girls to establish a correlationship between isoflavones in serum and precocious puberty; no diet history analysed; does not include a discussion on soya infant formulas Kattan, 2011 (121) Narrative review of soya allergy; no safety parameters on soya reported Dabeka, 2011 (122) Comparative analysis of aluminium in different food products for children; no safety parameters reported Degen, 2011 (123) Measurements of isoflavones in urine of 6-18-year-old children; no history about soya infant formulas reported Nguyen, 2011 (124) US measurements of different organs in children fed soya, cows' milk or HM; no mathematical data reported; only graphs and P values reported Jefferson, 2011 (125) Narrative review of basic, clinical and epidemiological studies of the effects of soya in animal models and human subjects; describes some important papers included in this review Durham, 2011 (126) Analysis of food allergy; no safety parameters on soya reported Levi, 2012 (127) Utility of atopy patch in atopic dermatitis; no safety parameters on soya reported Jefferson, 2012 (128) Narrative review of basic, clinical and epidemiological studies of the effects of soya in animal models and human subjects; describes some important papers included in this review Blom, 2012 (129) Analysis of allergy to soya; no other safety parameters reported Crinella, 2012 (130) Modern SIF contain P and Ca at concentrations that are about 20 % higher than those present in CMF. These formulas are supplemented with Fe and Zn, and the protease inhibitor activity has been removed by up to 90 %. In fact, a soyabean protease inhibitor with the properties of an antitrypsin, antichymotrypsin and antielastin as heated for infant formulas removes majority of this protease inhibitor activity and renders it nutritionally irrelevant. (4, 5) SIF have been indicated for use in children with cows' milk protein allergy and post-infectious diarrhoea due to lactose intolerance and galactosaemia, for use as a vegan HM substitute, and for the treatment of common feeding problems, such as fussiness, gas and spit-up. The American Academy of Pediatrics (AAP) supports the use of SPI-based formulas as safe and effective alternatives to provide appropriate nutrition for the normal growth and development of term infants whose nutritional needs are not being met by HM or formulas based on cows' milk (6) . Another important topic of discussion is phyto-oestrogens (isoflavones) present in SIF. Commercially, SIF contain 32 -47 mg/l of isoflavones, while mother's milk contains only 1-10 mg/l. The three main aglycones found in SIF are genistein, daidzein and, to a smaller extent, glycitein. Concerns have been raised about the genistein content of soya formulas because of its potential negative effects on sexual development and reproduction, neurobehavioural development, immune function and thyroid function (7, 8) .
However, soya formulas and other soya-based foods contain many components, of which genistein is only one. Chen & Rogan (9) reported that only 3·2-5·8 % of total isoflavones in soya formulas consist of unconjugated genistein and daidzein and that amounts can vary by batch. The majority (. 65 %) of isoflavones detected in soya formulas are conjugated to sugar molecules to form glycosides (10) . The levels of isoflavones in cord blood, amniotic fluid, HM, and infant plasma and urine have been measured, providing evidence that isoflavones pass from the mother to the infant and that they are absorbed from infant formulas (9 -12) . An international group of paediatricians and statisticians decided to conduct a meticulous review of available evidence to determine whether there is solid scientific evidence that SIF are not safe for infants. Therefore, the aims of the present study were to
Author, year, follow-up (months) SMD 95 % CI Weight (%)
Soya-flour or soya-protein infant formula (non-supplemented) Kay, 1960 (131) (3) Chan, 1987 (138) (4) Chan, 1987 (138) (4) Zoppi, 1982 (136) 
Venkataraman, 1992 (141) (4) Venkataraman, 1992 (141) (4) Giovannini, 1994 (143) (6) Giovannini, 1994 (143) (6) Andres, 2013 (147) (6) Andres, 2013 (147) (6) Lasekan, 1999 (144) (12) Seppo, 2005 (145) (12) Seppo, 2005 (145) (24) Han, 2011 (146) (36) Han, 2011 (146) (36) search for and evaluate all the available publications on the safety profile of SIF in children, with emphasis on the potentially negative effects on anthropometric growth, bone health, reproductive, endocrine and immune functions, and behaviour. The present review does not include an analysis of the safety of SIF in patients with cows' milk protein allergy. That topic will be discussed in a different publication.
Materials and methods

Studies included and their characteristics
Cross-sectional, case-control, cohort studies or clinical trials were included in the present systematic review if they were carried out in newborns, infants or children aged up to 18 years, independent of country of origin, language or clinical condition. For inclusion, papers were required to (1) be published in English or Spanish, (2) include the use of any type of SIF in at least one arm and (3) include a comparison with another type of infant formula for feeding purposes and measure/compare the effects of SIF on one or more of the following parameters: weight or height changes; Ca metabolism and/or bone mineral density; phyto-oestrogen levels in blood or urine (genistein, daidzein or equol); the effects of phyto-oestrogens on reproductive or endocrine functions (thyroid parameters); the effects on cognition and/ or behaviour. We also included papers that analysed the health effects of phytates and aluminium.
Search strategies
Highly sensitive evidence search strategies were employed as described by Wilczynski et al. (13) for the identification of observational studies and by Atkins et al. (14) for clinical trials, adding the keywords '(soy or soy and infant and formula) or (weight gain) or (height gain) or (hemoglobin changes) or (total and protein changes) or (albumin or globulin levels) or (zinc or calcium values) or (bone and mineral and content) or (genistein or daidzein; or equol levels) or (precocious and puberty) or (breast and bud) or (breast and Soya-flour or soya-protein infant formula (non-supplemented) Kay, 1960 (131) (3) Chan, 1987 (138) (4) Chan, 1987 (138) (4) Zoppi, 1982 (136) 
Venkataraman, 1992 (141) (4) Venkataraman, 1992 (141) (4) Giovannini, 1994 (143) (6) Giovannini, 1994 (143) (6) Andres, 2013 (147) (6) Andres, 2013 (147) (6) Mimouni, 1993 (142) (12) Mimouni, 1993 (142) (12) Seppo, 2005 (145) (12) Seppo, 2005 (145) (24) Han, 2011 (146) (36) Han, 2011 (146) (36)
Lasekan, 1999 (144) 
Note: Weights are from random-effects analysis
Seppo, 2005 (145) (24) Lasekan, 1999 (144) (12) 95 % CI Weight (%)
Favours soya infant formula Favours control group Author, year, follow-up (months) Kay, 1960 (131) (3) Zoppi, 1982 (136) 
Cherry, 1968 (132) (6)
Favours soya infant formula Favours control group 
Evidence quality evaluation
We used the standardised methods described by the Cochrane Collaboration for preparing the protocol, applying the criteria of inclusion, evaluating the quality of publications and extracting information. The quality of publications was determined using the GRADE system (14) . The GRADE approach specifies series/case reports) (14) . Using a double-blind and independent strategy, two authors extracted and evaluated the quality of relevant information in formats designed a priori for this purpose. Any disagreement in data collated was resolved by discussion and analysis of the information.
Synthesis and analysis of information
According to the GRADE system (14) , evidence obtained is presented in tables that report limitations in design, inconsistency, indirectness, imprecision, summary of findings and recommendations. The effects of soya on growth and development, reproductive and endocrinological functions, and immunity were meta-analysed using a Mantel -Haenszel fixed-effects model, and they are presented graphically by a forest plot. For all the estimates, a CI of 95 % was calculated. A heterogeneity test was carried out in all cases using the I 2 test, with a significant value of P, 0·05. In the case of suspected bias of publication, a funnel plot is presented. A sensitivity analysis was carried out, where necessary.
Results
Description and quality of studies
The initial search strategy yielded 156 potential studies (4,9 -12,15 -165) to be included. Upon careful review of the abstracts of each article, 121 (4,9 -12,15 -130) were eliminated (Table 1) , leaving a total of thirty-five articles for further analysis (131 -165) . The articles were eliminated because they covered topics not related to our safety analysis, were narrative reviews of the evidence, lacked sufficient congruence between what was described in the objectives and what was reported in the analysis, and/or did not contain sufficient extractable information to contribute to the goals of the present review.
Quantitative synthesis of results
Growth and development. Through the present systematic review, we identified fourteen randomised controlled trials (131 -138,141,143 -147) , which led us to identify the nutritional equivalence of SIF compared with that of HM and CMF regarding weight gain (standardised mean difference (SMD) 0·13, 95 % CI 2 0·15, 0·41, P¼ NS) and length gain (SMD 0·24, 95 % CI 2 0·10, 0·57, P¼NS) during the first year of life. At the same time, through this evidence analysis, we found no effects of these formulas on the levels of Hb (SMD 0·14, 95 % CI 2 0·52, 0·24, P¼ NS), total protein (SMD 20·08 
Favours soya infant formula Favours control group P¼ NS). Moreover, six randomised controlled trials (138 -142,147) allowed us to establish a safe profile for modern supplemented formulas with regard to bone mineral density (SMD 2 0·12, 95 % CI 2 1·46, 1·22, P¼NS; Table 2 ; Figs. 1 -7) . With regard to the potential negative effects of SIF on neurodevelopment, a study with an acceptable quality of evidence was conducted in 9-to 10-year-old children who were fed either SIF or HM during their first year of life. After adjusting for covariates, including ingestion of a chloride-deficient SIF, the authors did not find differences in intelligence quotient, behavioural problems, learning impairment or emotional problems (148) . Another study was conducted in 1999 among adults aged 20 -34 years, who, as infants, participated in controlled feeding studies from 1965 to 1978. The percentage of men or women who achieved some level of college or trade school education, whether fed SIF or CMF, did not differ (149) . A more recently published prospective cohort study compared the developmental status (i.e. mental, motor and language) of breast-fed (HM), CMF-fed and SIF-fed infants during the first year of life. A total of 391 healthy infants were assessed longitudinally at ages 3, 6, 9 and 12 months. Development was evaluated using the Bayley Scales of Infant Development and the Preschool Language Scale-3. Mixed-effects models were used while adjusting for socio-economic status, mother's age and intelligence quotient, gestational age, sex, birth weight, head circumference, race, age and diet history. No differences were found between the CMF-fed and SIFfed infants. The HM-fed babies had a small benefit in cognitive development compared with the formula-fed infants (150) . With regard to immune function and the risk of respiratory and gastrointestinal infections, we identified two randomised controlled trials (151, 153, 154) and one cohort study (152) Businco, 1990 (152) (RCTSB) -1·44, -0·23 33·97 Z = 0·17, P = 0·86; I 2 = 97·8 %, P = 0·0001 Businco, 1990 (152) low-to-moderate quality of evidence of similar behaviour between HM-fed, CMF-fed and SIF-fed children in relation to the percentage of B lymphocytes, T lymphocytes or natural killer cells, levels of IgA, IgG and IgM, and titration of antibodies against polio virus (SMD 2 0·39, 95 % CI 2 4·8, 4·01), diphtheria (SMD 28·10, 95 % CI 2 25·1, 8·89) or Haemophilus influenzae. We also found that the number of episodes/child of respiratory infections or acute diarrhoea was similar between the groups (SMD 1·25, 95 % CI 2 0·16, 2·33; Table 3 ; Figs. 8 -10 ). Phytate and aluminium toxicity. It is known that phytates can interfere with the intestinal absorption of Zn, Ca, Fe and P. None of the studies that we reviewed showed any negative impact of the content of phytates in SIF on anthropometric growth, Hb levels, and Ca and Zn serum levels in SIF-fed, CMF-fed children or breast-fed infants (132,136 -138,141,144 -146) ( Figs. 1 -7 ).
As has been described above, SIF contain higher levels of aluminium than CMF and HM. However, daily aluminium intake does not exceed 1 mg/kg, which is considered to be a tolerable level by the FAO/WHO (78) . Before the present systematic review, no published evidence has shown a negative health effect of aluminium in full-term infants fed modern SIF. In 2008, the AAP concluded that aluminium in SIF is not a safety issue, except when fed to preterm infants or infants with renal failure (155) . Reproductive and endocrine functions. We identified one randomised controlled trial and one cross-sectional study that demonstrated with a very low quality of evidence that there is an association of SIF intake with higher serum and urine levels of genistein (SMD 2·54, 95 % CI 2·07, 3·01, P 0·0001) and daidzein (SMD 4·68, 95 % CI 3·48, 5·87, P 0·0001) v. other feedings, but with similar equol levels (SMD 0·24, 95 % CI 29·34, 9·38, P¼ NS). These authors did not find significant correlations between the concentrations of isoflavones and the levels of certain hormones in children fed soya formulas (156, 157) . Despite convincing evidence of relatively high exposures, whether the isoflavones in SIF are biologically active in infants is an open question. If genistein, daidzein and equol are all oestrogenic in cell receptors and animals, the question appears to be primarily one of dose (157) . It is not conclusive what levels are biologically active and can produce organic effects. Importantly, some authors demonstrated that most of the phyto-oestrogens present in the plasma of SIF-fed infants are in a conjugated form and are therefore unable to exert hormonal effects. Our analysis of clinical evidence also produced inconclusive results (158) (Table 4 ; Figs. 11 and 12 ). From a clinical point of view, we identified two cohort studies (149, 153) with a moderate quality of evidence of marginal unfavourable effects of SIF on early menarche (SMD 2 0·36, 95 % CI 20·69, 20·02, P 0·04) and two studies with a very low quality of evidence (one cross-sectional study and one case -control study) where SIF seemed to be a risk factor for the presence of breast tissue during the second year of life (OR 2·44, 95 % CI 1·11, 5·39, P 0·01) (160, 161) . Additionally, in one of the cohort studies (149) , the authors identified an association of SIF intake with 9 h (95 % CI 1·5, 16 h) of more menstrual bleeding and more discomfort during menstrual periods (risk ratio 1·77, 95 % CI 1·04, 3·0, P 0·001). In other Moderate-quality evidence suggests no effect of soya on missed menstrual periods 12. Soya infant formula and discomfort during menstrual periods words, this study found only subtle effects including slight increases in the duration of women's menstrual cycles and the level of discomfort during menstruation. However, this study showed no statistically significant differences between groups in either women or men for more than thirty outcomes (e.g. precocious puberty, early thelarche, modification of cycle length, duration of menstrual bleeding, irregular menstrual periods, heavy menstrual flow, missed menstrual periods, spotting in the middle of a menstrual period, breast tenderness, frequency of pregnancies, and miscarriages or preterm deliveries) (Table 4 ; Fig. 13 ).
In 2010, a report about the possible association between uterine fibroids and SIF intake was published. In this cohort study with a low-to-moderate quality of evidence, the authors identified a risk ratio of 1·25, but with a CI of 0·97-1·61, associated with a non-significant P value (162) . With regard to SIF intake and potential association with endocrine dysfunction, interestingly, we found that most of these publications were published as case reports (43, 163, 164) . Messina et al. (165) reported no association between SIF intake and thyroid function disturbances in healthy infants with euthyroidism. These investigators identified fourteen trials in which the effects of soya foods or isoflavones on at least one measure of thyroid function were evaluated in healthy subjects: eight included only women; four involved only men; two included both men and women. With only one exception, either no effects or only very limited changes were observed in these trials. Thus together, the findings provide little evidence that in euthyroid, iodine-replete subjects, soya foods or isoflavones adversely affect thyroid function (165) .
Author, year (design) 
Discussion
Soya has been used as food throughout the world for thousands of years. Ruhräh (1) published the first report on the use of a soyabean-based formula for infants in 1909. Early SIF contained soya flour, a constituent with a poorer protein digestibility and a reduced protein content when compared with the SPI used in modern SIF. SPI replaced soya flour in infant formulas during the early 1960s. In the 1970s, methionine, iodine, carnitine, taurine, choline and inositol were added to standard SIF. Modern SIF meet the AAP recommendations and the Infant Formula Act (1980 and subsequent amendments in 1986) requirements for term infants (1 -4) . Approximately 25 % of infants in the USA are fed SIF at some point in their first year of life (AAP, 2008) (155) . Recently, some findings generated in animal models or human observations have challenged the use of these formulas in infants and children because of concerns about potential negative effects on growth, bone health, immunity, cognition, and reproductive or endocrine functions (74, 106) . The first review about soya was a narrative review published in 1988 that focused on growth and bone mineralisation. It was a result of concerns regarding adequate bone mineralisation when rickets was observed in very-low-birth-weight infants receiving soya-based feedings. This review concluded that children fed a soya isolate formula (old composition) had a pattern of growth similar to that of children fed a CMF and that infants fed a soya isolated formula had significantly lower bone mineral content and bone width at 3, 6, 9 and 12 months of age than those fed CMF, but that their values were similar to those of previously studied infants fed HM with vitamin D supplementation (32) . After the publication of this paper, at least eighteen additional narrative reviews on different aspects of safety and/or efficacy of SIF were published, most of them demonstrating a safety profile for use in children (4, 9, 49, 62, 66, 69, 74, 78, 86, 87, 91, 100, 106, 117, 121, 125, 128, 130) . In addition to these publications, only three systematic reviews with a meta-analysis were published about the efficacy of soya as an adjuvant in acute diarrhoea, infantile colic or cows' milk protein allergy prevention. In these publications, Brown et al. (43) assessed the effects of continued feeding of non-HM or formulas to infants during acute diarrhoea on their treatment failure rates, stool frequency and amount, diarrhoeal duration and body-weight change. They concluded that the vast majority of young children with acute diarrhoea can be successfully managed with continued feeding of undiluted non-HM. Lucassen et al. (55) concluded that in infants with infantile colic, the effectiveness of substitution with soya formula milks is unclear when only trials of good methodological quality are considered. Finally, Osborn & Sinn (82) concluded that soya formula feeding cannot be recommended for the prevention of allergy or food intolerance in infants at a high risk of allergy or food intolerance. To our knowledge, this is the first systematic review with a meta-analysis published with the focus mainly on SIF and safety in infants and children. It has the advantage of covering evidence analysis from 1909 to July 2013 (104 years), including papers published on SIF, non-enriched SIF and supplemented/enriched SIF. This extensive analysis objectively showed that SIF intake in normal full-term infants -even during the most rapid phase of growth -is associated with normal anthropometric growth, adequate protein status, bone mineralisation and normal immune development. The importance of the meta-analysis reported herein is that data demonstrate the negative effects of the 'old/unsupplemented soya formulas' on Ca metabolism and bone mineral content. For example, Chan et al. (138) studied the mineral metabolism in healthy term infants fed the old soya formula containing different sources of carbohydrates. Exclusively breast-fed infants served as controls. These investigators found that at 2 and 4 months of age, the breast-fed infants had higher bone mineral content and bone density. On the contrary, more recent studies using modern/ supplemented SIF have shown growth patterns, Ca levels, bone mineral content, serum Hb levels, total protein levels, immune factors, and upper respiratory or diarrhoeic infection risk similar to those found with other types of feedings. Few studies have evaluated the impact of SIF on neurodevelopment. For example, a study carried out by Malloy & Berendes (148) , in school-aged children who were fed either SIF or HM during their first year of life, showed no differences in intelligence quotient, behavioural problems, learning impairment or emotional problems. Strom et al. (149) conducted a study among adults aged 20 -34 years who, as infants, participated in controlled feeding studies. Results indicated no differences in men or women with regard to the achievements of the level of college or trade school education, whether they were fed SIF or CMF. Andres et al. (150) , in a more recent study in healthy infants, assessed the Bayley Scales of Infant Development and the Preschool Language Scale-3 during the first year of life. No differences were found between the CMFfed and SIF-fed infants. We are aware of the debate about differences in behaviour (mental, psychomotor and language) in breast-fed infants and formula-fed infants, which are not necessarily related only to the type of feedings. SPI contains 1 -2 % of phytates, which may impair the absorption of minerals and trace elements. Modern SIF contain higher levels of micronutrients (Ca, Zn, Fe, etc.) when compared with CMF or HM. We found that feeding SIF to young infants did not result in any negative impact on the levels of Hb, Zn, Ca and overall growth (Figs. 1 -3, 5 and 6 ). Similarly, we also found that SIF contain significantly higher levels of aluminium than CMF and HM (SIF 500-2500 mg/l, CMF 15 -400 mg/l and HM 4 -65 mg/l). This systematic review did not find any evidence of a negative health effect of this metal in children. SIF should not be fed to preterm infants or infants with renal failure. Studies have concluded that in term infants with normal renal function, there is no risk of aluminium toxicity from SIF.
Finally, it is known that phyto-oestrogens represent a broad group of plant-derived compounds of non-steroidal structure that are abundant within the plant kingdom, including soya, and have a weak oestrogenic activity. Minimum data are available on the potential effects of exposure to phyto-oestrogens in young children on later sexual and reproductive development. SIF-fed infants may have higher serum and urine levels of genistein and daidzein. As has been mentioned earlier, it seems that most of the phyto-oestrogens present in the plasma of SIF-fed infants are in a conjugated form and are therefore unable to exert hormonal effects (158) . The exhaustive analysis that we conducted in the present systematic review produced inconclusive results. We identified two cohort studies with a moderate quality of evidence of marginal adverse effects of SIF on early menarche. Furthermore, two other studies with a very low quality of evidence (one crosssectional study and one case -control study) showed that SIF would be a risk factor for the presence of breast tissue during the second year of life. Additionally, one cohort study identified an association of SIF intake with a significant increase in the duration of women's menstrual cycles and more discomfort during menstrual periods. However, the same study did not show any statistical difference between the groups for more than thirty additional outcomes, such as presence of puberty, early thelarche, modification of cycle length, severity of menstrual flow, irregular menstrual periods, heavy menstrual flow, missed menstrual periods, spotting in the middle of a menstrual period, breast tenderness, frequency of pregnancies, and miscarriages or preterm deliveries. This evidence analysis led us to establish that there is no significant effect of soya on important reproductive functions in human beings. The AAP has emphasised that literature reviews and clinical studies of infants fed SIF raise no clinical concerns with respect to nutritional adequacy, sexual development, thyroid disease, immune function or neurodevelopment. Additional studies confirm that SIF do not interfere with normal immune responses. The US Food and Drug Administration has also approved these formulas to be safe for use in infants.
